University of Illinois at Chicago
Exemption #JDR393
Announcement of an Exempt Purchase
Award Info Published Monday January 27, 2025
Novartis Pharmaceutical CorporationEast Hanover, NJ
- Amount: An estimated $31,500,000
- Terms: An estimated start date of 1/23/2025 through 6/30/2030
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Monday, January 27, 2025
The University awarded a contract for radiopharmaceuticals.
Pluvicto and Lutetium are FDA-approved radiopharmaceuticals used to treat prostate cancer and neuroendocrine tumors at UI Health. Since introducing these treatments in 2024, demand has grown significantly and is expected to grow further in coming years.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical at a university-operated health care center or dispensary that provides care, treatment, and medications for students, faculty and staff (30 ILCS 500 / 1-13(b-5)) Without these radiopharmaceuticals, the Hospital will not be able to provide care for the patients and will lose revenue.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.